Daglutril

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 328021

CAS#: 182821-27-8

Description: Daglutril, also known as SLV-306, is NEP/ECE inhibitor potentially for the treatment of hypertension, heart failure andpulmonary. SLV-306 (daglutril) inhibits systemic conversion of big endothelin-1 in humans.


Price and Availability

Size
Price

Size
Price

Size
Price

Daglutril is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 328021
Name: Daglutril
CAS#: 182821-27-8
Chemical Formula: C31H38N2O6
Exact Mass: 534.273
Molecular Weight: 534.653
Elemental Analysis: C, 69.64; H, 7.16; N, 5.24; O, 17.95


Synonym: Daglutril; SLV-306; SLV 306; SLV306.

IUPAC/Chemical Name: ((3S)-3-{1-((2R)-2-Ethoxycarbonyl-4-phenylbutyl)cyclopentanecarboxamido}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)acetic acid

InChi Key: XMQODGUTLZXUGZ-RPBOFIJWSA-N

InChi Code: InChI=1S/C31H38N2O6/c1-2-39-29(37)24(15-14-22-10-4-3-5-11-22)20-31(18-8-9-19-31)30(38)32-25-17-16-23-12-6-7-13-26(23)33(28(25)36)21-27(34)35/h3-7,10-13,24-25H,2,8-9,14-21H2,1H3,(H,32,38)(H,34,35)/t24-,25+/m1/s1

SMILES Code: O=C(O)CN1C([C@@H](NC(C2(C[C@H](C(OCC)=O)CCC3=CC=CC=C3)CCCC2)=O)CCC4=CC=CC=C41)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Márquez DF, Ruiz-Hurtado G, Ruilope LM, Segura J. An update of the blockade of the renin angiotensin aldosterone system in clinical practice. Expert Opin Pharmacother. 2015;16(15):2283-92. doi: 10.1517/14656566.2015.1079623. Epub 2015 Sep 7. Review. PubMed PMID: 26389772.

2: Maguire JJ, Davenport AP. Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12. Br J Pharmacol. 2014 Dec;171(24):5555-72. doi: 10.1111/bph.12874. Epub 2014 Nov 24. Review. PubMed PMID: 25131455; PubMed Central PMCID: PMC4290702.

3: Parvanova A, van der Meer IM, Iliev I, Perna A, Gaspari F, Trevisan R, Bossi A, Remuzzi G, Benigni A, Ruggenenti P; Daglutril in Diabetic Nephropathy Study Group. Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013 Sep;1(1):19-27. doi: 10.1016/S2213-8587(13)70029-9. Epub 2013 Jun 13. PubMed PMID: 24622263.

4: Laurent S. Daglutril for treatment of renal damage in hypertensive patients with type 2 diabetes: disappointment or hope? Lancet Diabetes Endocrinol. 2013 Sep;1(1):2-3. doi: 10.1016/S2213-8587(13)70036-6. Epub 2013 Jun 13. PubMed PMID: 24622251.

5: Monge M, Lorthioir A, Bobrie G, Azizi M. New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension. J Renin Angiotensin Aldosterone Syst. 2013 Dec;14(4):285-9. doi: 10.1177/1470320313513408. Epub 2013 Nov 12. Review. PubMed PMID: 24222656.

6: Seed A, Kuc RE, Maguire JJ, Hillier C, Johnston F, Essers H, de Voogd HJ, McMurray J, Davenport AP. The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8. doi: 10.1016/j.lfs.2012.03.022. Epub 2012 Mar 28. PubMed PMID: 22480515.

7: Thöne-Reinke C, Simon K, Richter CM, Godes M, Neumayer HH, Thormählen D, Hocher B. Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S76-9. PubMed PMID: 15838365.

8: Emoto N. [Physiological and pathophysiological roles of the endothelin converting enzymes]. Nihon Rinsho. 2004 Sep;62 Suppl 9:636-9. Review. Japanese. PubMed PMID: 15506464.

9: Dickstein K, De Voogd HJ, Miric MP, Willenbrock R, Mitrovic V, Pacher R, Koopman PA. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol. 2004 Jul 15;94(2):237-9. PubMed PMID: 15246912.

10: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 May;25(4):317-40. PubMed PMID: 12808477.

11: Tabrizchi R. SLV-306. Solvay. Curr Opin Investig Drugs. 2003 Mar;4(3):329-32. Review. PubMed PMID: 12735234.

12: Gray GA, Battistini B, Webb DJ. Endothelins are potent vasoconstrictors, and much more besides. Trends Pharmacol Sci. 2000 Feb;21(2):38-40. PubMed PMID: 10733432.